RAS(ON) Therapies on the Horizon to Address KRAS Resistance: Highlight on a Phase III Clinical Candidate Daraxonrasib (RMC-6236)

Authors

Zonghui Ma, Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch (UTMB), Galveston, Texas 77555, United States.
Mingxiang Zhou, Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch (UTMB), Galveston, Texas 77555, United States.
Qiang Shen, LSU Health Sciences Center - New OrleansFollow
Jia Zhou, Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch (UTMB), Galveston, Texas 77555, United States.

Document Type

Editorial

Publication Date

6-26-2025

Publication Title

Journal of medicinal chemistry

First Page

12287

Last Page

12292

PubMed ID

40566958

Volume

68

Issue

12

Recommended Citation

Ma, Zonghui; Zhou, Mingxiang; Shen, Qiang; and Zhou, Jia, "RAS(ON) Therapies on the Horizon to Address KRAS Resistance: Highlight on a Phase III Clinical Candidate Daraxonrasib (RMC-6236)" (2025). School of Medicine Faculty Publications. 3903.
https://digitalscholar.lsuhsc.edu/som_facpubs/3903
10.1021/acs.jmedchem.5c01441